Understanding DXS International's Impact on Hypertension Care
DXS International plc: Enhancing Healthcare Efficiency
DXS INTERNATIONAL PLC (AQSE: DXSP)
At the forefront of digital clinical decision support solutions, DXS International plc is excited to announce the prominent role of its innovative solution, ExpertCare, within a recent assessment by the renowned York Health Economics Consortium (YHEC). Their evaluation underscores ExpertCare's impressive influence on patient outcomes and its cost-effectiveness within the NHS framework.
Jointly funded by DXS and Innovate UK, this comprehensive study is in collaboration with Health Innovation East and examines ExpertCare's effectiveness in managing medication optimization for patients with hypertension. The assessment spanned 2,484 patients across 13 GP practices, analyzing the performance of ExpertCare against traditional methods for hypertension reviews.
The findings from the evaluation indicate that ExpertCare not only enhances hypertension control but also minimizes treatment variability, proving to be financially beneficial in both immediate and extended timelines.
Key Findings from the YHEC Report
The YHEC report highlighted several critical advancements facilitated by ExpertCare:
- There is a notable increase in the number of patients experiencing optimal hypertension management with ExpertCare.
- The return on investment for every £1 allocated to ExpertCare is an impressive £2.70 for the NHS.
How ExpertCare Works
ExpertCare serves as a sophisticated clinical decision support mechanism that simplifies data gathering and formulates treatment recommendations adhering to NICE guidelines. This capability not only alleviates the burden on clinical staff but also significantly enhances patient outcomes across the board.
David Immelman, CEO of DXS, remarked:
“The independent validation results fill us with confidence. We strongly believe that ExpertCare can revolutionize hypertension management throughout England, simultaneously alleviating the financial pressures on the NHS. These findings underscore the tangible benefits of rolling out ExpertCare on a national scale from the very first year.”
For anyone interested in learning more about DXS International plc and its innovative initiatives, additional information is available.
Contact Information
Contacts:
David Immelman
DXS International plc
www.dxs-systems.com
01252 719800
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce
020 3764 2341
About DXS International
DXS International specializes in delivering current treatment protocols and recommendations sourced from Clinical Commissioning Groups and respected NHS entities directly to healthcare professionals. This integration fosters enhanced clinical decision-making, ultimately leading to elevated healthcare outcomes that are more economically viable. Such advancements are vital as the NHS strives towards significant efficiency improvements.
Frequently Asked Questions
What is ExpertCare?
ExpertCare is a digital clinical decision support tool designed to enhance healthcare delivery by optimizing medication management for patients, particularly in hypertension.
How does ExpertCare improve patient outcomes?
By streamlining data collection and adhering to established clinical guidelines, ExpertCare enables more effective hypertension control and better management of treatment variances.
What were the results of the YHEC report?
The YHEC report confirmed that ExpertCare significantly boosts the number of patients with optimally managed hypertension while offering substantial cost savings to the NHS.
What is DXS International's mission?
DXS International aims to improve healthcare outcomes through digital solutions that are easily integrated into healthcare providers' workflows, ultimately enhancing the treatment process.
What are the financial benefits of using ExpertCare?
For every £1 spent on ExpertCare, the NHS benefits from a return of £2.70, demonstrating its cost-effectiveness in managing healthcare resources.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.